Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD

References

• BegheBRabeKFFabbriLMPhosphodiesterase-4 inhibitor therapy for lung diseasesAm J Respir Crit Care Med2013188327127810.1164/rccm.201301-0021PP23656508
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMBredenbrokerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPDRespir Res2011121810.1186/1465-9921-12-12221272339
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786610.1016/S0140-6736(14)62410-725684586
   PubMed Web of Science ®Google Scholar
• CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176215416110.1164/rccm.200610-1563OC17463412
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 11418142210.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• SeneffMGWagnerDPWagnerRPZimmermanJEKnausWAHospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary diseaseJAMA199527423185218577500534
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593110.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• BatemanEDRabeKFCalverleyPMRoflumilast with long-acting beta2-agonists for COPD: influence of exacerbation historyEur Respir J201138355356010.1183/09031936.0017871021737553
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569410.1016/S0140-6736(09)61255-119716960
   PubMed Web of Science ®Google Scholar
• HwangHShinJYParkKREffect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary diseaseTuberc Respir Dis (Seoul)201578432132510.4046/trd.2015.78.4.32126508918
   PubMedGoogle Scholar
• Munoz-EsquerreMDiez-FerrerMMontonCRoflumilast added to triple therapy in patients with severe COPD: a real life studyPulm Pharmacol Ther201530162110.1016/j.pupt.2014.10.00225445930
   PubMed Web of Science ®Google Scholar
• MichalskiJMGoldenGIkariJRennardSIPDE4: a novel target in the treatment of chronic obstructive pulmonary diseaseClin Pharmacol Ther201291113414210.1038/clpt.2011.26622130119
   PubMed Web of Science ®Google Scholar
• PinnerNAHamiltonLAHughesARoflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseClin Ther2012341566610.1016/j.clinthera.2011.12.00822284994
   PubMed Web of Science ®Google Scholar
• CalverleyPMMartinezFJFabbriLMGoehringUMRabeKFDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538210.2147/COPD.S3110022791991
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570310.1016/S0140-6736(09)61252-619716961
   PubMed Web of Science ®Google Scholar
• GuptaSSide-effects of roflumilastLancet20123799817710711 author reply 711–71210.1016/S0140-6736(12)60304-322364756
   PubMed Web of Science ®Google Scholar
• WatzHBagulNRabeKFUse of a 4-week up-titration regimen of roflumilast in patients with severe COPDInt J Chron Obstruct Pulmon Dis20181381382210.2147/COPD.S15401229563781
   PubMed Web of Science ®Google Scholar
• LimJULeeJHKimJSComparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patientsInt J Chron Obstruct Pulmon Dis2017122465247510.2147/COPD.S14129528860741
   PubMed Web of Science ®Google Scholar
• KimKHKangHSKimJSYoonHKKimSKRheeCKRisk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2017123449345610.2147/COPD.S14396729270006
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDWitteSBredenbrokerDBethkeTDRoflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357110.1016/S0140-6736(05)67100-016099292
   PubMed Web of Science ®Google Scholar
• LeeJSHongYKParkTSLeeSWOhYMLeeSDEfficacy and safety of roflumilast in Korean patients with COPDYonsei Med J201657492893510.3349/ymj.2016.57.4.92827189287
   PubMed Web of Science ®Google Scholar
• LeeSDHuiDSMahayiddinAARoflumilast in Asian patients with COPD: A randomized placebo-controlled trialRespirology20111681249125710.1111/j.1440-1843.2011.02038.x21848706
   PubMed Web of Science ®Google Scholar
• LiuD-YWangZ-GGaoYEffect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patientsMedicine (Baltimore)2018977e986410.1097/MD.000000000000986429443750
   PubMed Web of Science ®Google Scholar
• JooHHanDLeeJHRheeCKIncidence of adverse effects and discontinuation rate between patients receiving 250 micrograms and 500 micrograms of roflumilast: A comparative studyTuberc Respir Dis (Seoul)201881429930410.4046/trd.2018.001529926552
   PubMed Web of Science ®Google Scholar
• ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyChest20141451445210.1378/chest.13-125224135893
   PubMed Web of Science ®Google Scholar
• GuengerichFPCytochrome p450 and chemical toxicologyChem Res Toxicol2008211708310.1021/tx700079z18052394
   PubMed Web of Science ®Google Scholar
• LahuGNassrNHünnemeyerAPharmacokinetic evaluation of roflumilastExpert Opin Drug Metab Toxicol20117121577159110.1517/17425255.2011.63240922059647
   PubMed Web of Science ®Google Scholar
• RabeKFUpdate on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBr J Pharmacol20111631536710.1111/j.1476-5381.2011.01218.x21232047
   PubMed Web of Science ®Google Scholar
• LeeJSCheongHSKimLHScreening of genetic polymorphisms of CYP3A4 and CYP3A5 GenesKorean J Physiol Pharmacol201317647948410.4196/kjpp.2013.17.6.47924381495
   PubMed Web of Science ®Google Scholar